{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:17Z","timestamp":1793018117842,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01926-4","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:49:46Z","timestamp":1791035386000},"page":"5405-5427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Retinoids in Cutaneous T-Cell Lymphoma: A Scoping Review of Clinical Use and Evidence Gaps"],"prefix":"10.1007","volume":"16","author":[{"given":"Toan","family":"Bui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keon","family":"Niknejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Urbanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya Goksu","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Wolner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"1926_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2023. Eur J Cancer. 2023;195:113343. https:\/\/doi.org\/10.1016\/j.ejca.2023.113343.","journal-title":"Eur J Cancer"},{"key":"1926_CR2","doi-asserted-by":"publisher","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(1):193\u2013209. https:\/\/doi.org\/10.1002\/ajh.26760. [Erratum in: Am J Hematol. 2026 Jan;101(1):222. 10.1002\/ajh.70135].","DOI":"10.1002\/ajh.26760"},{"key":"1926_CR3","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (1999, December 29). Approval letter for NDA 21-055: Targretin (bexarotene) capsules. U.S. Department of Health and Human Services"},{"issue":"5","key":"1926_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","volume":"19","author":"C Zhang","year":"2006","unstructured":"Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther. 2006;19(5):264\u201371. https:\/\/doi.org\/10.1111\/j.1529-8019.2006.00083.x.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1926_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/bjd.21772","volume":"187","author":"G Roccuzzo","year":"2022","unstructured":"Roccuzzo G, Fava P, Avallone G, Aquino C, Boskovic S, Macagno N, et al. Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. Br J Dermatol. 2022;187(6):1019\u201321. https:\/\/doi.org\/10.1111\/bjd.21772.","journal-title":"Br J Dermatol"},{"key":"1926_CR6","unstructured":"Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581\u201393."},{"issue":"2","key":"1926_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","volume":"68","author":"J Cheeley","year":"2013","unstructured":"Cheeley J, Sahn RE, DeLong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68(2):247\u201354. https:\/\/doi.org\/10.1016\/j.jaad.2012.07.013.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1926_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5114\/pdia.2013.33375","volume":"30","author":"M Soko\u0142owska-Wojdy\u0142o","year":"2013","unstructured":"Soko\u0142owska-Wojdy\u0142o M, Lugowska-Umer H, Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol. 2013;30(1):19\u201329. https:\/\/doi.org\/10.5114\/pdia.2013.33375.","journal-title":"Postepy Dermatol Alergol"},{"issue":"9","key":"1926_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69318","volume":"16","author":"S Ayuthu","year":"2024","unstructured":"Ayuthu S, Chauhan YD, Mirza AA, Saad MZ, Bittla P, Paidimarri SP, et al. Role of retinoids and their analogs in the treatment of cutaneous T-cell lymphoma: a systematic review. Cureus. 2024;16(9):e69318. https:\/\/doi.org\/10.7759\/cureus.69318.","journal-title":"Cureus"},{"issue":"1","key":"1926_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","journal-title":"Int J Soc Res Methodol"},{"key":"1926_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69.","journal-title":"Implement Sci"},{"issue":"3","key":"1926_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","volume":"13","author":"MD Peters","year":"2015","unstructured":"Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141\u20136. https:\/\/doi.org\/10.1097\/XEB.0000000000000050.","journal-title":"Int J Evid Based Healthc"},{"issue":"7","key":"1926_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"key":"1926_CR14","doi-asserted-by":"publisher","unstructured":"Bui T. Systemic retinoid therapy in cutaneous T-cell lymphoma: a scoping review of clinical use, treatment contexts, and evidence gaps. 2026. https:\/\/doi.org\/10.17605\/OSF.IO\/RD28H","DOI":"10.17605\/OSF.IO\/RD28H"},{"key":"1926_CR15","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https:\/\/www.R-project.org\/."},{"key":"1926_CR16","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Primary cutaneous lymphomas (Version 2.2026). 2026. https:\/\/www.nccn.org"},{"issue":"1","key":"1926_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1067\/mjd.2003.449","volume":"49","author":"M Duvic","year":"2003","unstructured":"Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;49(1):35\u201349. https:\/\/doi.org\/10.1067\/mjd.2003.449.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1926_CR18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/cncr.22596","volume":"109","author":"DJ Straus","year":"2007","unstructured":"Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007;109(9):1799\u2013803. https:\/\/doi.org\/10.1002\/cncr.22596.","journal-title":"Cancer"},{"issue":"2","key":"1926_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.transci.2011.10.029","volume":"46","author":"MP Siakantaris","year":"2012","unstructured":"Siakantaris MP, Tsirigotis P, Stavroyianni N, Argyropoulos KV, Girkas K, Pappa V, et al. Management of cutaneous T-cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. Transfus Apher Sci. 2012;46(2):189\u201393. https:\/\/doi.org\/10.1016\/j.transci.2011.10.029.","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"1926_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1067\/mjd.2001.110645","volume":"44","author":"U Wollina","year":"2001","unstructured":"Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol. 2001;44(2):253\u201360. https:\/\/doi.org\/10.1067\/mjd.2001.110645.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1926_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","volume":"138","author":"KR Suchin","year":"2002","unstructured":"Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054\u201360. https:\/\/doi.org\/10.1001\/archderm.138.8.1054.","journal-title":"Arch Dermatol"},{"issue":"12","key":"1926_CR22","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","volume":"147","author":"BA Raphael","year":"2011","unstructured":"Raphael BA, Shin DB, Suchin KR, Morrissey KA, Vittorio CC, Kim EJ, et al. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol. 2011;147(12):1410\u20135. https:\/\/doi.org\/10.1001\/archdermatol.2011.232.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1926_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","volume":"106","author":"F Foss","year":"2005","unstructured":"Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005;106(2):454\u20137. https:\/\/doi.org\/10.1182\/blood-2004-11-4570.","journal-title":"Blood"},{"issue":"3","key":"1926_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00128071-200809030-00005","volume":"9","author":"E Papadavid","year":"2008","unstructured":"Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol. 2008;9(3):169\u201373. https:\/\/doi.org\/10.2165\/00128071-200809030-00005.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1926_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1684\/ejd.2015.2672","volume":"26","author":"S Rupoli","year":"2016","unstructured":"Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, et al. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and\/or relapsed patients with mycosis fungoides. Eur J Dermatol. 2016;26(1):13\u201320. https:\/\/doi.org\/10.1684\/ejd.2015.2672.","journal-title":"Eur J Dermatol"},{"key":"1926_CR26","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.718","volume":"102","author":"J Rouanet","year":"2022","unstructured":"Rouanet J, Joulie I, Lambert C, D\u2019Incan M. Real-life use of bexarotene for T-cell cutaneous lymphoma management: efficacy and tolerance with low doses. Acta Derm Venereol. 2022;102:adv00746. https:\/\/doi.org\/10.2340\/actadv.v102.718.","journal-title":"Acta Derm Venereol"},{"issue":"21","key":"1926_CR27","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","volume":"7","author":"BA Campbell","year":"2023","unstructured":"Campbell BA, Dobos G, Haider Z, Prince HM, Bagot M, Evison F, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):6639\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2023011041.","journal-title":"Blood Adv"},{"issue":"4","key":"1926_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","volume":"51","author":"F Singh","year":"2004","unstructured":"Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. 2004;51(4):570\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2003.05.010.","journal-title":"J Am Acad Dermatol"},{"key":"1926_CR29","doi-asserted-by":"publisher","unstructured":"Rodrigues FT, Cabral GCCC, Alvim PFMF, Junior DDAD, Ciganha LS, Leal JM, Scotelaro MFG, Gripp AC. Milia en plaque on the shoulder as an early manifestations of mycosis fungoides. Dermatol Online J. 2024;30(1). https:\/\/doi.org\/10.5070\/D330163296.","DOI":"10.5070\/D330163296"},{"issue":"9","key":"1926_CR30","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456\u201371. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2456.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1926_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","volume":"42","author":"HM Prince","year":"2001","unstructured":"Prince HM, McCormack C, Ryan G, Baker C, Rotstein H, Davison J, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol. 2001;42(2):91\u20137. https:\/\/doi.org\/10.1046\/j.1440-0960.2001.00488.x.","journal-title":"Australas J Dermatol"},{"issue":"2-3","key":"1926_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.trim.2011.06.008","volume":"25","author":"M Schlaak","year":"2011","unstructured":"Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, Scheid C, Chemnitz J, Stadler R, et al. Donor lymphocyte infusions combined with systemic PUVA\/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl Immunol. 2011;25(2\u20133):163\u20136. https:\/\/doi.org\/10.1016\/j.trim.2011.06.008.","journal-title":"Transpl Immunol"},{"key":"1926_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12524","author":"DJ Lewis","year":"2017","unstructured":"Lewis DJ, Huang S, Duvic M. Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12524.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1926_CR34","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/archderm.144.6.738","volume":"144","author":"P Gerami","year":"2008","unstructured":"Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738\u201346. https:\/\/doi.org\/10.1001\/archderm.144.6.738.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1926_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000324185","volume":"3","author":"I Cervig\u00f3n-Gonz\u00e1lez","year":"2011","unstructured":"Cervig\u00f3n-Gonz\u00e1lez I, Torres-Iglesias LM, Palomo-Arellano A, Gil-Pascual B. Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol. 2011;3(1):13\u20137. https:\/\/doi.org\/10.1159\/000324185.","journal-title":"Case Rep Dermatol"},{"issue":"12","key":"1926_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/1346-8138.15114","volume":"46","author":"H Kamijo","year":"2019","unstructured":"Kamijo H, Sugaya M. Two distinct variants of mycosis fungoides (MF): folliculotropic MF and erythrodermic MF. J Dermatol. 2019;46(12):1136\u201340. https:\/\/doi.org\/10.1111\/1346-8138.15114.","journal-title":"J Dermatol"},{"key":"1926_CR37","doi-asserted-by":"publisher","unstructured":"Del Guzzo CA, Jariwala NN, Haun PL, MacArthur KM, Mowad CM, Richard EG, Holton JP, Rook AH. Pilot Study of a Novel Therapeutic Approach for Refractory Advanced Stage Folliculotropic Mycosis Fungoides. Acta Derm Venereol. 2020;100(13):adv00187. https:\/\/doi.org\/10.2340\/00015555-3443.","DOI":"10.2340\/00015555-3443"},{"issue":"12","key":"1926_CR38","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/ijd.15561","volume":"60","author":"IJ Moon","year":"2021","unstructured":"Moon IJ, Lee KH, Choi JW, Lee WJ, Won CH, Chang S, et al. Clinical characteristics and long-term outcomes of 97 Korean patients with mycosis fungoides. Int J Dermatol. 2021;60(12):1510\u20139. https:\/\/doi.org\/10.1111\/ijd.15561.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1926_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","volume":"50","author":"KS McGinnis","year":"2004","unstructured":"McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol. 2004;50(3):375\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2003.10.669.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1926_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1517\/14656566.2013.810718","volume":"14","author":"G Qu\u00e9reux","year":"2013","unstructured":"Qu\u00e9reux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dr\u00e9no B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother. 2013;14(13):1711\u201321. https:\/\/doi.org\/10.1517\/14656566.2013.810718.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1926_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/1346-8138.14923","volume":"46","author":"T Hamada","year":"2019","unstructured":"Hamada T, Tokura Y, Sugaya M, Ohtsuka M, Tsuboi R, Nagatani T, et al. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: the results of a phase 2 study (B-1201). J Dermatol. 2019;46(7):557\u201363. https:\/\/doi.org\/10.1111\/1346-8138.14923.","journal-title":"J Dermatol"},{"issue":"1","key":"1926_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1365-2141.2009.07596.x","volume":"145","author":"A Musolino","year":"2009","unstructured":"Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. Br J Haematol. 2009;145(1):84\u20136. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07596.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"1926_CR43","first-page":"115","volume":"4","author":"B Sariakcali","year":"2014","unstructured":"Sariakcali B, Jamaspishvili E, Evran M, Sert M, Tetiker T. Bexarotene-induced dyslipidemia and central hypothyroidism in a patient with Sezary syndrome. J Endocrinol Metabol. 2014;4(4):115\u20137.","journal-title":"J Endocrinol Metabol"},{"issue":"3","key":"1926_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ced.13044","volume":"42","author":"I Cabello","year":"2017","unstructured":"Cabello I, Servitje O, Corbella X, Bard\u00e9s I, Pint\u00f3 X. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clin Exp Dermatol. 2017;42(3):276\u201381. https:\/\/doi.org\/10.1111\/ced.13044.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1926_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000488447","volume":"11","author":"C Maminakis","year":"2018","unstructured":"Maminakis C, Whitman AC, Islam N. Bexarotene-induced hypertriglyceridemia: a case report. Case Rep Oncol. 2018;11(1):234\u20138. https:\/\/doi.org\/10.1159\/000488447.","journal-title":"Case Rep Oncol"},{"issue":"2","key":"1926_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jaad.2025.09.074","volume":"94","author":"PB Allen","year":"2026","unstructured":"Allen PB, Goyal S, Iyer S, Talluru S, Huen A, Greenwell B, et al. Racial differences in mycosis fungoides and S\u00e9zary syndrome: a multicenter cohort study. J Am Acad Dermatol. 2026;94(2):509\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.074.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1926_CR47","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","volume":"20","author":"A Aviles","year":"2015","unstructured":"Aviles A, Neri N, Fernandez-Diez J, Silva L, Nambo MJ. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma. Hematology (Amsterdam). 2015;20(9):538\u201342. https:\/\/doi.org\/10.1179\/1607845415Y.0000000002.","journal-title":"Hematology (Amsterdam)"},{"issue":"3","key":"1926_CR48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-021-00655-0","volume":"12","author":"A Morita","year":"2022","unstructured":"Morita A, Tateishi C, Ikumi K, Hayashi D, Nakada A, Nishihara H, et al. Comparison of the efficacy and safety of bexarotene and photo(chemo)therapy combination therapy and bexarotene monotherapy for cutaneous T-cell lymphoma. Dermatol Ther (Heidelb). 2022;12(3):615\u201329. https:\/\/doi.org\/10.1007\/s13555-021-00655-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1926_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamadermatol.2020.3958","volume":"157","author":"JS Durgin","year":"2021","unstructured":"Durgin JS, Jariwala NN, Wysocka M, Zhang KK, Maity A, Benoit B, et al. Low-dose total skin electron beam therapy as part of a multimodality regimen for treatment of S\u00e9zary syndrome: clinical, immunologic, and molecular analysis. JAMA Dermatol. 2021;157(1):90\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3958.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1926_CR50","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/j.1600-0625.2009.00993.x","volume":"19","author":"AC Knol","year":"2010","unstructured":"Knol AC, Qu\u00e9reux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, et al. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Exp Dermatol. 2010;19(8):e95-102. https:\/\/doi.org\/10.1111\/j.1600-0625.2009.00993.x.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1926_CR51","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/j.1440-0960.2012.00944.x","volume":"54","author":"A Kakizaki","year":"2013","unstructured":"Kakizaki A, Fujimura T, Mizuashi M, Watabe A, Kambayashi Y, Aiba S. Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids. Australas J Dermatol. 2013;54(4):e82\u20134. https:\/\/doi.org\/10.1111\/j.1440-0960.2012.00944.x.","journal-title":"Australas J Dermatol"},{"issue":"12","key":"1926_CR52","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/DAD.0000000000002259","volume":"44","author":"C Santonja","year":"2022","unstructured":"Santonja C, S\u00e1nchez-Garc\u00eda FJ, Rodr\u00edguez-Rodr\u00edguez RN, Manso R, Requena L, Gil-Mateo MDP, et al. Double CD4\/CD8-positive, nonpoikilodermic mycosis fungoides expressing CD56 in a young man. Am J Dermatopathol. 2022;44(12):936\u20139. https:\/\/doi.org\/10.1097\/DAD.0000000000002259.","journal-title":"Am J Dermatopathol"},{"key":"1926_CR53","doi-asserted-by":"publisher","unstructured":"Obijiofor C, Yin E, Shvartsbeyn M, Latkowski JA, Ahearn I, Gutierrez D. Tache and talon noir in patient with mycosis fungoides on acitretin. Dermatol Online J. 2023;29(4). https:\/\/doi.org\/10.5070\/D329461918.","DOI":"10.5070\/D329461918"},{"issue":"1","key":"1926_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","volume":"51","author":"C Querfeld","year":"2004","unstructured":"Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004;51(1):25\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2003.11.058.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1926_CR55","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","volume":"53","author":"R Dummer","year":"2012","unstructured":"Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012;53(8):1501\u20138. https:\/\/doi.org\/10.3109\/10428194.2012.656625.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1926_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1534734614534978","volume":"13","author":"I Zindanci","year":"2014","unstructured":"Zindanci I, Kavala M, Turko\u011flu Z, Can B, Ozturk E, Zemheri E, et al. A CD30(-) Transformed mycosis fungoides case responding very well to systemic bexarotene and methotrexate. Int J Low Extrem Wounds. 2014;13(2):127\u20139. https:\/\/doi.org\/10.1177\/1534734614534978.","journal-title":"Int J Low Extrem Wounds"},{"issue":"6","key":"1926_CR57","doi-asserted-by":"publisher","first-page":"716","DOI":"10.29271\/jcpsp.2021.06.716","volume":"31","author":"F Tamer","year":"2021","unstructured":"Tamer F, Gulekon A. Novel inflammatory biomarkers in patients with mycosis fungoides treated with bexarotene. J Coll Physicians Surg Pak. 2021;31(6):716\u20138. https:\/\/doi.org\/10.29271\/jcpsp.2021.06.716.","journal-title":"J Coll Physicians Surg Pak"},{"key":"1926_CR58","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/BF02505252","volume":"288","author":"GP Rajan","year":"1996","unstructured":"Rajan GP, Seifer B, Pr\u00fcmmer O, et al. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch Dermatol Res. 1996;288:543\u20138. https:\/\/doi.org\/10.1007\/BF02505252.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"1926_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520966896","volume":"48","author":"G Gour-Proven\u00e7al","year":"2020","unstructured":"Gour-Proven\u00e7al G, Newman NM, Boudier-Rev\u00e9ret M, Chang MC. Severe acitretin-induced diffuse idiopathic skeletal hyperostosis: a case report. J Int Med Res. 2020;48(10):300060520966896. https:\/\/doi.org\/10.1177\/0300060520966896.","journal-title":"J Int Med Res"},{"issue":"1","key":"1926_CR60","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21231","volume":"14","author":"HY Alojail","year":"2022","unstructured":"Alojail HY, Alshehri H, Kaliyadan F. Clinical patterns and treatment response of patients with mycosis fungoides a retrospective study. Cureus. 2022;14(1):e21231. https:\/\/doi.org\/10.7759\/cureus.21231.","journal-title":"Cureus"},{"issue":"Suppl 1","key":"1926_CR61","first-page":"67","volume":"26","author":"A Stein","year":"2008","unstructured":"Stein A. Bexarotene monotherapy for patients with refractory early stage mycosis fungoides. Dermatol Clin. 2008;26(Suppl 1):67\u201370.","journal-title":"Dermatol Clin"},{"issue":"10","key":"1926_CR62","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/bjc.2013.616","volume":"109","author":"T Illidge","year":"2013","unstructured":"Illidge T, Chan C, Counsell N, Morris S, Scarisbrick J, Gilson D, et al. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer. 2013;109(10):2566\u201373. https:\/\/doi.org\/10.1038\/bjc.2013.616.","journal-title":"Br J Cancer"},{"key":"1926_CR63","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/jvc2.514","volume":"3","author":"I Hansen-Abeck","year":"2024","unstructured":"Hansen-Abeck I, Blomen CL, Abeck F, Torster L, Schneider SW, Booken N. Posttransplantation course after allogeneic stem cell transplantation in a patient with advanced mycosis fungoides\u2014balancing relapse and rejection. JEADV Clin Pract. 2024;3:1660\u20134. https:\/\/doi.org\/10.1002\/jvc2.514.","journal-title":"JEADV Clin Pract"},{"issue":"12","key":"1926_CR64","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2018.3679","volume":"154","author":"I Cabello","year":"2018","unstructured":"Cabello I, Alia P, Pint\u00f3 X, Muniesa C, Fernandez-de-Misa R, Pe\u00f1ate Y, et al. Association of APOA5 and APOC3 genetic polymorphisms with severity of hypertriglyceridemia in patients with cutaneous T-cell lymphoma treated with bexarotene. JAMA Dermatol. 2018;154(12):1424\u201331. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3679.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1926_CR65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/09546634.2018.1487525","volume":"30","author":"I Amitay-Laish","year":"2019","unstructured":"Amitay-Laish I, Reiter O, Prag-Naveh H, Kershenovich R, Hodak E. Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work? J Dermatolog Treat. 2019;30(3):258\u201363. https:\/\/doi.org\/10.1080\/09546634.2018.1487525.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1926_CR66","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1046\/j.1439-0353.2003.03711.x","volume":"1","author":"J Bohmeyer","year":"2003","unstructured":"Bohmeyer J, Stadler R, Kremer A, Nashan D, Muche M, Gellrich S, et al. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. J Dtsch Dermatol Ges. 2003;1(10):785\u20139. https:\/\/doi.org\/10.1046\/j.1439-0353.2003.03711.x.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"1926_CR67","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaad.2006.10.033","volume":"56","author":"JA Sepmeyer","year":"2007","unstructured":"Sepmeyer JA, Greer JP, Koyama T, Zic JA. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2007;56(4):584\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2006.10.033.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1926_CR68","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/DAD.0000000000000609","volume":"38","author":"WT Johnson","year":"2016","unstructured":"Johnson WT, Leeman-Neill RJ, Patel P, Ho J, Grandinetti LM, Jedrych J, et al. Fatal case of primary cutaneous aggressive T-cell lymphoma switching from a CD4+ to a CD8+ phenotype: progressive disease with bexarotene and romidepsin treatment. Am J Dermatopathol. 2016;38(11):832\u20137. https:\/\/doi.org\/10.1097\/DAD.0000000000000609.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"1926_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.222","volume":"3","author":"J Yamamoto","year":"2023","unstructured":"Yamamoto J, Ohuchi K, Amagai R, Roh Y, Endo J, Chiba H, et al. CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomas. Skin Health Dis. 2023;3(3):e222. https:\/\/doi.org\/10.1002\/ski2.222.","journal-title":"Skin Health Dis"},{"key":"1926_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.884091","volume":"12","author":"K Polg\u00e1rov\u00e1","year":"2022","unstructured":"Polg\u00e1rov\u00e1 K, Pol\u00edvka J, Kodet O, Klener P, Trn\u011bn\u00fd M. Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience. Front Oncol. 2022;12:884091. https:\/\/doi.org\/10.3389\/fonc.2022.884091.","journal-title":"Front Oncol"},{"issue":"3","key":"1926_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09546630802562427","volume":"20","author":"AP Kannangara","year":"2009","unstructured":"Kannangara AP, Levitan D, Fleischer AB Jr. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat. 2009;20(3):169\u201376. https:\/\/doi.org\/10.1080\/09546630802562427.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1926_CR72","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/archderm.139.6.771","volume":"139","author":"KS McGinnis","year":"2003","unstructured":"McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol. 2003;139(6):771\u20135. https:\/\/doi.org\/10.1001\/archderm.139.6.771.","journal-title":"Arch Dermatol"},{"issue":"9","key":"1926_CR73","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archderm.141.9.1176","volume":"141","author":"KS McGinnis","year":"2005","unstructured":"McGinnis KS, Ubriani R, Newton S, Junkins-Hopkins JM, Vittorio CC, Kim EJ, et al. The addition of interferon gamma to oral bexarotene therapy with photopheresis for S\u00e9zary syndrome. Arch Dermatol. 2005;141(9):1176\u20138. https:\/\/doi.org\/10.1001\/archderm.141.9.1176.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1926_CR74","first-page":"E30","volume":"99","author":"K Eshagh","year":"2017","unstructured":"Eshagh K, Romero LS, So JK, Zhao XF. Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient. Cutis. 2017;99(2):E30\u20134.","journal-title":"Cutis"},{"issue":"2","key":"1926_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/095466301317085435","volume":"12","author":"GJ Kontochristopoulos","year":"2001","unstructured":"Kontochristopoulos GJ, Exadaktylou D, Hatziolou E, Tassidou A, Zakopoulou N. Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin. J Dermatolog Treat. 2001;12(2):117\u201321. https:\/\/doi.org\/10.1080\/095466301317085435.","journal-title":"J Dermatolog Treat"},{"key":"1926_CR76","unstructured":"Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1989;69(6):536\u20138."},{"issue":"14","key":"1926_CR77","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-16-2064","volume":"23","author":"M Duvic","year":"2017","unstructured":"Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I\/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed\/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017;23(14):3552\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2064.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1926_CR78","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/s0190-9622(96)90282-0","volume":"34","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;34(6):1022\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(96)90282-0.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1926_CR79","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1097\/MJT.0000000000000056","volume":"23","author":"M Sokolowska-Wojdylo","year":"2016","unstructured":"Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, et al. Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. Am J Ther. 2016;23(3):e749\u201356. https:\/\/doi.org\/10.1097\/MJT.0000000000000056.","journal-title":"Am J Ther"},{"issue":"1","key":"1926_CR80","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-4632.2007.03147.x","volume":"46","author":"M Rodr\u00edguez-V\u00e1zquez","year":"2007","unstructured":"Rodr\u00edguez-V\u00e1zquez M, Garc\u00eda-Arpa M, Gonz\u00e1lez-Garc\u00eda J. Juvenile mycosis fungoides treated with bexarotene and PUVA. Int J Dermatol. 2007;46(1):99\u2013102. https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03147.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1926_CR81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s0190-9622(03)02488-5","volume":"50","author":"MA Huber","year":"2004","unstructured":"Huber MA, Kunzi-Rapp K, Staib G, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol. 2004;50(3):475\u20136. https:\/\/doi.org\/10.1016\/s0190-9622(03)02488-5.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1926_CR82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jdcr.2017.03.012","volume":"3","author":"MIBL Puno","year":"2017","unstructured":"Puno MIBL, Dimagiba MTE, Jamora MJJ, Montinola FL, Tinio PT. Granulomatous slack skin presenting as diffuse poikiloderma and necrotic ulcers, with features of granulomatous vasculitis and response to oral prednisone, acitretin, and oral psoralen plus ultraviolet light therapy-A case report. JAAD Case Rep. 2017;3(4):294\u2013300. https:\/\/doi.org\/10.1016\/j.jdcr.2017.03.012.","journal-title":"JAAD Case Rep"},{"issue":"21","key":"1926_CR83","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.26355\/eurrev_202211_30166","volume":"26","author":"M Teoli","year":"2022","unstructured":"Teoli M, Mandel VD, Franceschini C, Saraceni PL, Cicini MP, Ardig\u00f2 M. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. Eur Rev Med Pharmacol Sci. 2022;26(21):8118\u201328. https:\/\/doi.org\/10.26355\/eurrev_202211_30166.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1926_CR84","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1507\/endocrj.EJ21-0313","volume":"69","author":"N Toi","year":"2022","unstructured":"Toi N, Kurajoh M, Miyaoka D, Nagata Y, Yamada S, Imanishi Y, et al. Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. Endocr J. 2022;69(1):101\u20135. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0313.","journal-title":"Endocr J"},{"issue":"11","key":"1926_CR85","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.clml.2020.06.020","volume":"20","author":"MR Kudelka","year":"2020","unstructured":"Kudelka MR, Switchenko JM, Lechowicz MJ, Esiashvili N, Flowers CR, Khan MK, et al. Maintenance therapy for cutaneous T-cell lymphoma after total skin electron irradiation: evidence for improved overall survival with ultraviolet therapy. Clin Lymphoma Myeloma Leuk. 2020;20(11):757-767.e3. https:\/\/doi.org\/10.1016\/j.clml.2020.06.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"1926_CR86","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","volume":"167","author":"S Whittaker","year":"2012","unstructured":"Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol. 2012;167(3):678\u201387. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11156.x.","journal-title":"Br J Dermatol"},{"issue":"5 Suppl 1","key":"1926_CR87","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jaad.2007.07.012","volume":"58","author":"M Steinhoff","year":"2008","unstructured":"Steinhoff M, Beyer M, Roewert-Huber J, Lukowsky A, Assaf C, Sterry W. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol. 2008;58(5 Suppl 1):S88-91. https:\/\/doi.org\/10.1016\/j.jaad.2007.07.012.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1926_CR88","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","volume":"15","author":"M Polansky","year":"2015","unstructured":"Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with S\u00e9zary syndrome. Clin Lymphoma Myeloma Leuk. 2015;15(5):e83-93. https:\/\/doi.org\/10.1016\/j.clml.2014.09.013.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1926_CR89","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jaad.2021.07.013","volume":"86","author":"M O'Donnell","year":"2022","unstructured":"O\u2019Donnell M, Zaya R, Correia E, Krishnasamy S, Sahu J, Shi W, et al. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: a single-center retrospective study. J Am Acad Dermatol. 2022;86(6):1285\u201392. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.013.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1926_CR90","first-page":"417","volume":"73","author":"MA Mehlmauer","year":"2004","unstructured":"Mehlmauer MA. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene. Cutis. 2004;73(6):417\u201320.","journal-title":"Cutis"},{"key":"1926_CR91","unstructured":"Oren-Shabtai M, Levi A, Mimouni D, Prag-Naveh H, Didkovsky E, Pokroy-Shapira E, Hodak E, Amitay-Laish I. Coexistence of mycosis fungoides and photosensitive or autoimmune diseases. The therapeutic challenge: a retrospective case series from a tertiary referral center. Isr Med Assoc J. 2025;27(6):346\u2013352."},{"issue":"6","key":"1926_CR92","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1067\/mjd.2002.124816","volume":"47","author":"M Shapiro","year":"2002","unstructured":"Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47(6):956\u201361. https:\/\/doi.org\/10.1067\/mjd.2002.124816.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1926_CR93","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1600-0781.2007.00315.x","volume":"23","author":"ML Lokitz","year":"2007","unstructured":"Lokitz ML, Wong HK. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatol Photoimmunol Photomed. 2007;23(6):255\u20137. https:\/\/doi.org\/10.1111\/j.1600-0781.2007.00315.x.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"1926_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nmd.2021.11.009","volume":"32","author":"M Hiebeler","year":"2022","unstructured":"Hiebeler M, Reinholz M, Flaig M, Schmidt C, Schoser B, Herzinger T, et al. Cutaneous T-cell lymphoma mimicking myopathy with lipoatrophy. Neuromuscul Disord. 2022;32(1):65\u201370. https:\/\/doi.org\/10.1016\/j.nmd.2021.11.009.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"1926_CR95","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/1346-8138.15310","volume":"47","author":"A Morita","year":"2020","unstructured":"Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, et al. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. J Dermatol. 2020;47(5):443\u201351. https:\/\/doi.org\/10.1111\/1346-8138.15310.","journal-title":"J Dermatol"},{"issue":"5","key":"1926_CR96","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61164","volume":"16","author":"N Sasaki","year":"2024","unstructured":"Sasaki N, Akamatsu Y, Ogaya A, Oda T, Ohmori S, Okada E, et al. Mycosis fungoides presenting with multiple tumors on the face. Cureus. 2024;16(5):e61164. https:\/\/doi.org\/10.7759\/cureus.61164.","journal-title":"Cureus"},{"issue":"6","key":"1926_CR97","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00128071-200304060-00006","volume":"4","author":"N Apisarnthanarax","year":"2003","unstructured":"Apisarnthanarax N, Ha CS, Duvic M. Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation: successful treatment using radiation therapy plus oral bexarotene combination therapy. Am J Clin Dermatol. 2003;4(6):429\u201333. https:\/\/doi.org\/10.2165\/00128071-200304060-00006.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1926_CR98","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1111\/jdv.16567","volume":"34","author":"V Nikolaou","year":"2020","unstructured":"Nikolaou V, Patsatsi A, Sidiropoulou P, Chlouverakis G, Kavvalou E, Koletsa T, et al. Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. J Eur Acad Dermatol Venereol. 2020;34(11):2534\u201340. https:\/\/doi.org\/10.1111\/jdv.16567.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1926_CR99","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cen.13975","volume":"91","author":"N Makita","year":"2019","unstructured":"Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T. Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies. Clin Endocrinol (Oxf). 2019;91(1):195\u2013200. https:\/\/doi.org\/10.1111\/cen.13975.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"1926_CR100","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.3816\/clm.2000.s.009","volume":"1","author":"P Heald","year":"2000","unstructured":"Heald P. The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clin Lymphoma. 2000;1(Suppl 1):S45\u20139. https:\/\/doi.org\/10.3816\/clm.2000.s.009.","journal-title":"Clin Lymphoma"},{"issue":"6","key":"1926_CR101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ad.2023.12.007","volume":"115","author":"R Izu-Belloso","year":"2024","unstructured":"Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fern\u00e1ndez de Misa-Cabrera R, Pe\u00f1ate Y, et al. Experience with bexarotene to treat cutaneous T-cell lymphomas: a study of the Spanish working group of cutaneous lymphomas. Actas Dermosifiliogr. 2024;115(6):547\u201354. https:\/\/doi.org\/10.1016\/j.ad.2023.12.007.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1926_CR102","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","volume":"160","author":"RA Abbott","year":"2009","unstructured":"Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome. Br J Dermatol. 2009;160(6):1299\u2013307. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09037.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1926_CR103","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2009.02.035","volume":"62","author":"RH Gormley","year":"2010","unstructured":"Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol. 2010;62(2):300\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2009.02.035.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1926_CR104","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000512484","volume":"237","author":"R Alhusayen","year":"2021","unstructured":"Alhusayen R, Vu TT, Almuhanna N, Wohlmuth-Wieser I, Hardin J, Hughes JM, et al. Evaluation of alitretinoin for the treatment of mycosis fungoides and S\u00e9zary syndrome. Dermatology (Basel). 2021;237(3):479\u201385. https:\/\/doi.org\/10.1159\/000512484.","journal-title":"Dermatology (Basel)"},{"issue":"4","key":"1926_CR105","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","volume":"14","author":"R Talpur","year":"2014","unstructured":"Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2014;14(4):297\u2013304. https:\/\/doi.org\/10.1016\/j.clml.2014.01.010.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1926_CR106","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3816\/CLM.2006.n.031","volume":"6","author":"R Talpur","year":"2006","unstructured":"Talpur R, Duvic M. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. Clin Lymphoma Myeloma. 2006;6(6):488\u201392. https:\/\/doi.org\/10.3816\/CLM.2006.n.031.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"1926_CR107","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","volume":"11","author":"R Talpur","year":"2011","unstructured":"Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2011;11(2):219\u201327. https:\/\/doi.org\/10.1016\/j.clml.2011.03.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1926_CR108","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1067\/mjd.2002.124607","volume":"47","author":"R Talpur","year":"2002","unstructured":"Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47(5):672\u201384. https:\/\/doi.org\/10.1067\/mjd.2002.124607.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1926_CR109","doi-asserted-by":"publisher","first-page":"568","DOI":"10.2340\/00015555-1114","volume":"91","author":"A Ranki","year":"2011","unstructured":"Ranki A, V\u00e4kev\u00e4 L, Sipil\u00e4 L, Krohn K. Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. Acta Derm Venereol. 2011;91(5):568\u201373. https:\/\/doi.org\/10.2340\/00015555-1114.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1926_CR110","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ajh.21231","volume":"83","author":"S Gopaluni","year":"2008","unstructured":"Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, et al. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. Am J Hematol. 2008;83(9):744\u20136. https:\/\/doi.org\/10.1002\/ajh.21231.","journal-title":"Am J Hematol"},{"issue":"2 Pt 1","key":"1926_CR111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","volume":"24","author":"RM Knobler","year":"1991","unstructured":"Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991;24(2 Pt 1):247\u201352. https:\/\/doi.org\/10.1016\/0190-9622(91)70036-2.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1926_CR112","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-4632.2004.02132.x","volume":"44","author":"RA el-Azhary","year":"2005","unstructured":"el-Azhary RA, Bouwhuis SA. Oral bexarotene in a therapy-resistant S\u00e9zary syndrome patient: observations on S\u00e9zary cell compartmentalization. Int J Dermatol. 2005;44(1):25\u20138. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02132.x.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1926_CR113","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00432-020-03449-7","volume":"147","author":"D Rolf","year":"2021","unstructured":"Rolf D, Elsayad K, Eich HT. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma. J Cancer Res Clin Oncol. 2021;147(6):1757\u201361. https:\/\/doi.org\/10.1007\/s00432-020-03449-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1926_CR114","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1365-2133.2005.07034.x","volume":"154","author":"A Ruiz-de-Casas","year":"2006","unstructured":"Ruiz-de-Casas A, Carrizosa-Esquivel A, Herrera-Saval A, Rios-Mart\u00edn JJ, Camacho F. S\u00e9zary syndrome associated with granulomatous lesions during treatment with bexarotene. Br J Dermatol. 2006;154(2):372\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.07034.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1926_CR115","doi-asserted-by":"publisher","DOI":"10.5070\/D3231033672","volume":"23","author":"S Narala","year":"2017","unstructured":"Narala S, Cohen PR. Cutaneous T-cell lymphoma-associated Leser-Tr\u00e9lat sign: report and world literature review. Dermatol Online J. 2017;23(1):13030\/qt0w01b1t3.","journal-title":"Dermatol Online J"},{"issue":"6","key":"1926_CR116","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jacl.2015.08.004","volume":"9","author":"S Basani","year":"2015","unstructured":"Basani S, Garg A. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. J Clin Lipidol. 2015;9(6):832\u20136. https:\/\/doi.org\/10.1016\/j.jacl.2015.08.004.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1926_CR117","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40268-024-00465-7","volume":"24","author":"A Sanagawa","year":"2024","unstructured":"Sanagawa A, Hayakawa T, Yamamoto A, Hotta Y, Furukawa-Hibi Y, Morita A. Effects of body mass index on hypertriglyceridemia associated with oral Bexarotene therapy: a post hoc analysis of an open-label comparative clinical study of combined Bexarotene and phototherapy versus Bexarotene monotherapy for Japanese patients with cutaneous T-cell lymphoma. Drugs R D. 2024;24(2):227\u201338. https:\/\/doi.org\/10.1007\/s40268-024-00465-7.","journal-title":"Drugs R D"},{"issue":"1","key":"1926_CR118","first-page":"48","volume":"26","author":"S Jerkovi\u0107 Gulin","year":"2018","unstructured":"Jerkovi\u0107 Gulin S, \u010ceovi\u0107 R, Ili\u0107 I, Bradamante M, Bukvi\u0107 Mokos Z, Kostovi\u0107 K. Poikilodermatous mycosis fungoides\u2014rare entity, different treatment modalities. Acta Dermatovenerol Croat. 2018;26(1):48\u201352.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"3","key":"1926_CR119","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2005.11.1051","volume":"54","author":"ST Kim","year":"2006","unstructured":"Kim ST, Jeon YS, Sim HJ, Kim SH, Kim YK, Suh KS, et al. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris. J Am Acad Dermatol. 2006;54(3):466\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1051.","journal-title":"J Am Acad Dermatol"},{"key":"1926_CR120","doi-asserted-by":"publisher","unstructured":"Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR. Bexarotene treatment of late-stage mycosis fungoides and S\u00e9zary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol. 2005;52(6):991\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2005.02.055.","DOI":"10.1016\/j.jaad.2005.02.055"},{"issue":"1","key":"1926_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-020-00087-3","volume":"6","author":"S DeAngelo","year":"2020","unstructured":"DeAngelo S, Mann KI, Abdulbasit M, Ahnert A, Sundl\u00f6f DW. A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene). Cardiooncology. 2020;6(1):31. https:\/\/doi.org\/10.1186\/s40959-020-00087-3.","journal-title":"Cardiooncology"},{"issue":"7","key":"1926_CR122","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S1578-2190(08)70314-7","volume":"99","author":"S P\u00e9rez-Barrio","year":"2008","unstructured":"P\u00e9rez-Barrio S, Izu R, Garc\u00eda-Ruiz JC, Acebo E, Mart\u00ednez de Lagr\u00e1n Z, D\u00edaz-P\u00e9rez JL. Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides. Actas Dermosifiliogr (Engl Ed). 2008;99(7):560\u20134. https:\/\/doi.org\/10.1016\/S1578-2190(08)70314-7.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"1","key":"1926_CR123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2310\/7750.2012.12022","volume":"17","author":"S Gregoriou","year":"2013","unstructured":"Gregoriou S, Rigopoulos D, Stamou C, Nikolaou V, Kontochristopoulos G. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas. J Cutan Med Surg. 2013;17(1):52\u20134. https:\/\/doi.org\/10.2310\/7750.2012.12022.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1926_CR124","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3816\/CLM.2006.n.063","volume":"7","author":"SK Richardson","year":"2006","unstructured":"Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, et al. High clinical response rate with multimodality immunomodulatory therapy for S\u00e9zary syndrome. Clin Lymphoma Myeloma. 2006;7(3):226\u201332. https:\/\/doi.org\/10.3816\/CLM.2006.n.063.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"23","key":"1926_CR125","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","volume":"5","author":"SM Horwitz","year":"2021","unstructured":"Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098\u2013106. https:\/\/doi.org\/10.1182\/bloodadvances.2021004710.","journal-title":"Blood Adv"},{"issue":"14","key":"1926_CR126","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","volume":"340","author":"SI Sherman","year":"1999","unstructured":"Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340(14):1075\u20139. https:\/\/doi.org\/10.1056\/NEJM199904083401404.","journal-title":"N Engl J Med"},{"issue":"1","key":"1926_CR127","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/annonc\/mdt480","volume":"25","author":"DJ Straus","year":"2014","unstructured":"Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, et al. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014;25(1):206\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdt480.","journal-title":"Ann Oncol"},{"issue":"6","key":"1926_CR128","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/1346-8138.15322","volume":"47","author":"T Fujimura","year":"2020","unstructured":"Fujimura T, Sato Y, Tanita K, Amagai R, Shimauchi T, Ogata D, et al. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. J Dermatol. 2020;47(6):636\u201340. https:\/\/doi.org\/10.1111\/1346-8138.15322.","journal-title":"J Dermatol"},{"issue":"3","key":"1926_CR129","doi-asserted-by":"publisher","first-page":"457","DOI":"10.30476\/mejc.2022.94274.1719","volume":"14","author":"S Torabi","year":"2023","unstructured":"Torabi S, Fakhraei S, Tayebi Meibodi N, Ahmadpour F. Spiny hyperkeratosis-like follicular mycosis fungoides: a case report. Middle East J Cancer. 2023;14(3):457\u201362. https:\/\/doi.org\/10.30476\/mejc.2022.94274.1719.","journal-title":"Middle East J Cancer"},{"issue":"3","key":"1926_CR130","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cncr.20009","volume":"100","author":"AM Tsimberidou","year":"2004","unstructured":"Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004;100(3):574\u201380. https:\/\/doi.org\/10.1002\/cncr.20009.","journal-title":"Cancer"},{"issue":"3","key":"1926_CR131","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","volume":"92","author":"L V\u00e4kev\u00e4","year":"2012","unstructured":"V\u00e4kev\u00e4 L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012;92(3):258\u201363. https:\/\/doi.org\/10.2340\/00015555-1359.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1926_CR132","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11591","volume":"12","author":"V Pattan","year":"2020","unstructured":"Pattan V, Schaab K, Sundaresh V. Bexarotene: a rare cause of misleading thyroid function tests. Cureus. 2020;12(11):e11591. https:\/\/doi.org\/10.7759\/cureus.11591.","journal-title":"Cureus"},{"issue":"12","key":"1926_CR133","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1002\/ajh.24564","volume":"91","author":"W Hanel","year":"2016","unstructured":"Hanel W, Briski R, Ross CW, Anderson TF, Kaminski MS, Hristov AC, et al. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol. 2016;91(12):E491\u20135. https:\/\/doi.org\/10.1002\/ajh.24564.","journal-title":"Am J Hematol"},{"issue":"11","key":"1926_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111948","volume":"16","author":"K Wojewoda","year":"2024","unstructured":"Wojewoda K, Gillstedt M, Lewerin C, Osmancevic A. S\u00e9zary syndrome in West Sweden: exploring epidemiology, clinical features, and treatment patterns in a registry-based retrospective analysis. Cancers (Basel). 2024;16(11):1948. https:\/\/doi.org\/10.3390\/cancers16111948.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1926_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5021\/ad.2013.25.2.259","volume":"25","author":"YR Woo","year":"2013","unstructured":"Woo YR, Lee HM, Lee JS, Koo DW. Long-term follow-up of refractory mycosis fungoides which achieved remission with the addition of isotretinoin to methotrexate and psoralen plus ultraviolet A therapy. Ann Dermatol. 2013;25(2):259\u201360. https:\/\/doi.org\/10.5021\/ad.2013.25.2.259.","journal-title":"Ann Dermatol"},{"issue":"2021","key":"1926_CR136","doi-asserted-by":"publisher","first-page":"5527725","DOI":"10.1155\/2021\/5527725","volume":"1","author":"Y Kageyama","year":"2021","unstructured":"Kageyama Y, Tsuda K, Nato Y, Nagaharu K, Suzuki K, Sawaki A, et al. S\u00e9zary syndrome with CD4\/CD8 double-negative neoplastic T cells in peripheral blood. Case Rep Hematol. 2021;1(2021):5527725. https:\/\/doi.org\/10.1155\/2021\/5527725.","journal-title":"Case Rep Hematol"},{"issue":"6","key":"1926_CR137","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2340\/0001555564563566","volume":"64","author":"K Thomsen","year":"1984","unstructured":"Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1984;64(6):563\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 1","key":"1926_CR138","first-page":"27","volume":"26","author":"M Bagot","year":"2008","unstructured":"Bagot M. Treatment of S\u00e9zary syndrome with bexarotene after IFNalpha and methotrexate failure. Dermatol Clin. 2008;26(Suppl 1):27\u20139.","journal-title":"Dermatol Clin"},{"issue":"2","key":"1926_CR139","first-page":"134","volume":"1","author":"DK Stern","year":"2002","unstructured":"Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol. 2002;1(2):134\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"suppl 1","key":"1926_CR140","first-page":"61","volume":"26","author":"G Staib","year":"2008","unstructured":"Staib G, Scharffetter-Kochanek K. Bexarotene monotherapy for patients with refractory S\u00e9zary syndrome. Dermatol Clin. 2008;26(suppl 1):61\u20133.","journal-title":"Dermatol Clin"},{"issue":"10","key":"1926_CR141","first-page":"3578","volume":"92","author":"R Stadler","year":"1998","unstructured":"Stadler R, Otte HG, Luger T, Henz BM, K\u00fchl P, Zwingers T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92(10):3578\u201381.","journal-title":"Blood"},{"key":"1926_CR142","unstructured":"Shistik G, Scalf LA, Fenske N, Glass LF. Follicular mycosis fungoides: successful treatment with oral bexarotene. J Drugs Dermatol. 2004;3(3):301\u20134."},{"issue":"Suppl 1","key":"1926_CR143","first-page":"55","volume":"26","author":"A Ranki","year":"2008","unstructured":"Ranki A. Bexarotene combination therapy for patients with S\u00e9zary syndrome. Dermatol Clin. 2008;26(Suppl 1):55\u20137.","journal-title":"Dermatol Clin"},{"issue":"Suppl 1","key":"1926_CR144","first-page":"51","volume":"26","author":"B Otremba","year":"2008","unstructured":"Otremba B. Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy. Dermatol Clin. 2008;26(Suppl 1):51\u20132.","journal-title":"Dermatol Clin"},{"key":"1926_CR145","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000078595","volume":"209","author":"S Michaelis","year":"2004","unstructured":"Michaelis S, Cozzio A, Kempf W, Graf P, Burg G, Dummer R. Combination of bexarotene and psoralen-UVA therapy in a patient with mycosis fungoides. Dermatology. 2004;209:72\u20134.","journal-title":"Dermatology"},{"issue":"suppl 1","key":"1926_CR146","first-page":"45","volume":"26","author":"M Kamstrup","year":"2008","unstructured":"Kamstrup M, Gniadecki R. Bexarotene monotherapy for epidermotropic CD8+ CTCL. Dermatol Clin. 2008;26(suppl 1):45\u20137.","journal-title":"Dermatol Clin"},{"issue":"4","key":"1926_CR147","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1684\/ejd.2020.3840","volume":"30","author":"S Novelli","year":"2020","unstructured":"Novelli S, Mart\u00edn A, S\u00e1nchez JJ, Espeso M, Mozos A, Briones J. Management experience of advanced-stage mycosis fungoides\/S\u00e9zary syndrome: a retrospective study from Spanish haematology referral units. Eur J Dermatol. 2020;30(4):397\u2013403. https:\/\/doi.org\/10.1684\/ejd.2020.3840.","journal-title":"Eur J Dermatol"},{"issue":"8338","key":"1926_CR148","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/s0140-6736(83)92136-0","volume":"1","author":"JF Kessler","year":"1983","unstructured":"Kessler JF, Meyskens FL Jr, Levine N, Lynch PJ, Jones SE. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983;1(8338):1345\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(83)92136-0.","journal-title":"Lancet"},{"issue":"10","key":"1926_CR149","doi-asserted-by":"publisher","DOI":"10.5070\/D30GM267V6","volume":"17","author":"E Berger","year":"2011","unstructured":"Berger E, Altiner A, Chu J, Patel R, Sanders S, Latkowski JA. Mycosis fungoides stage IB progressing to cutaneous tumors. Dermatol Online J. 2011;17(10):5.","journal-title":"Dermatol Online J"},{"issue":"6","key":"1926_CR150","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1524-4725.1986.tb01961.x","volume":"12","author":"JE Fitzpatrick","year":"1986","unstructured":"Fitzpatrick JE, Mellette JR. Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol. 1986;12(6):626\u20139. https:\/\/doi.org\/10.1111\/j.1524-4725.1986.tb01961.x.","journal-title":"J Dermatol Surg Oncol"},{"issue":"4","key":"1926_CR151","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000305354","volume":"220","author":"F Ballanger","year":"2010","unstructured":"Ballanger F, Nguyen JM, Khammari A, Dr\u00e9no B. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology (Basel). 2010;220(4):370\u20135. https:\/\/doi.org\/10.1159\/000305354.","journal-title":"Dermatology (Basel)"},{"issue":"4","key":"1926_CR152","first-page":"487","volume":"12","author":"J Huang","year":"2013","unstructured":"Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. J Drugs Dermatol. 2013;12(4):487\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1926_CR153","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5070\/D34ZD5429J","volume":"13","author":"B Firoz","year":"2007","unstructured":"Firoz B, Kovich OI, Latkowski JA. Mycosis fungoides with depigmentation secondary to treatment. Dermatol Online J. 2007;13(1):18.","journal-title":"Dermatol Online J"},{"issue":"4","key":"1926_CR154","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1684\/ejd.2021.4085","volume":"31","author":"F Furukawa","year":"2021","unstructured":"Furukawa F, Makino T, Torai R, Mori S, Terada Y, Seki T, et al. Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides. Eur J Dermatol. 2021;31(4):567\u20138. https:\/\/doi.org\/10.1684\/ejd.2021.4085.","journal-title":"Eur J Dermatol"},{"issue":"suppl 1","key":"1926_CR155","first-page":"25","volume":"26","author":"H Bachelez","year":"2008","unstructured":"Bachelez H. Bexarotene monotherapy for patients with advanced stage mycosis fungoides. Dermatol Clin. 2008;26(suppl 1):25\u20136.","journal-title":"Dermatol Clin"},{"issue":"suppl 1","key":"1926_CR156","first-page":"33","volume":"26","author":"E Coors","year":"2008","unstructured":"Coors E. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides. Dermatol Clin. 2008;26(suppl 1):33\u20135.","journal-title":"Dermatol Clin"},{"issue":"suppl 1","key":"1926_CR157","first-page":"39","volume":"26","author":"S Dalle","year":"2008","unstructured":"Dalle S, Thomas L. Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon\/PUVA and methotrexate. Dermatol Clin. 2008;26(suppl 1):39\u201341.","journal-title":"Dermatol Clin"},{"key":"1926_CR158","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/1346-8138.16201","volume":"49","author":"T Hamada","year":"2022","unstructured":"Hamada T, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, et al. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: real-world experience from post-marketing surveillance. J Dermatol. 2022;49:253\u201362. https:\/\/doi.org\/10.1111\/1346-8138.16201.","journal-title":"J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01926-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:05Z","timestamp":1793016365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01926-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":158,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01926-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Toan Bui has nothing to disclose. Keon Niknejad has nothing to disclose. Nicholas Urbanski has nothing to disclose. Derya Goksu Fidan has nothing to disclose. Zachary Wolner has nothing to disclose. Sima Rozati has consulted for Kyowa Kirin and Citius.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required because this study involved analysis of published literature and did not involve human participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}